In summary, our study demonstrates that XZK has higher hypotriglyceridemic performance than simvastatin with an equivalent LDL-C lowering power, which supports XZK as a superior choice for CHD patients with modestly increased LDL-C but markedly elevated TG, wherein more hepatic apoA5 synthesis by this agent is involved via the signaling PPARα pathway. The gene discussed is PPARA; the disease is coronary artery disorder.